Personalized medicine reveals its potential in the face of global health challenges in 2026
Eleven precision medicine clinical trials converge in 2026 to transform the management of cancer, infectious diseases, and autoimmune conditions. New tuberculosis vaccines show 50% efficacy, while mRNA-based CAR-T therapies achieve 57% complete remission in patients with myasthenia gravis.
This convergence of personalized innovations reveals medicine capable of precisely targeting the pathological mechanisms of each patient. This approach allows treatment to be adapted to the specific molecular characteristics of each tumor or disease, identifying the precise abnormalities to target with targeted therapies, immunotherapy, or specific chemotherapies.
The Essentials
- The M72/AS01E tuberculosis vaccine shows 49.7% efficacy in phase 3, and mRNA CAR-T therapies achieve 57% remission in myasthenia gravis
- Trials include mRNA-based CAR-T therapies for myasthenia gravis and cellular immunotherapies for metastatic breast cancer
- Two new pancreatic cancer drugs double survival: daraxonrasib (13.2 months vs 6.7) and elraglusib (doubling one-year survival)
- Innovations cover tuberculosis, Lassa fever, pancreatic and breast cancers, with 20,000 participants expected for phase 3 trials
The Tuberculosis Vaccine Reaches a Decisive Milestone
The M72/AS01E vaccine from GlaxoSmithKline maintains 49.7% efficacy against pulmonary tuberculosis after 36 months of follow-up in adults infected with Mycobacterium tuberculosis. This performance meets the criteria of the World Health Organization, which requires at least 50% efficacy for tuberculosis vaccines.
The phase 3 trial mobilizes 54 sites across five countries—Indonesia, Kenya, Malawi, South Africa, and Zambia—with the objective of recruiting 20,000 adolescent and adult participants. The vaccine combines a recombinant fusion protein derived from two M. tuberculosis antigens (Mtb32A and Mtb39A) with the AS01E adjuvant system.
Trials in South Africa involving 3,500 HIV-positive patients confirm vaccine tolerance with an acceptable safety profile, generating robust immune responses both humoral and cellular. The current BCG vaccine offers limited protection against pulmonary tuberculosis in adolescents and adults. M72/AS01E aims to prevent the progression of latent infection to active tuberculosis.
mRNA-Based CAR-T Therapies Redefine Autoimmune Treatment
The Descartes-08 trial evaluates a CAR-T therapy using mRNA to temporarily reprogram T cells in the treatment of myasthenia gravis, achieving 57% of patients in near-complete remission at six months. Participants maintain these results through twelve months of follow-up.
Unlike traditional CAR-T therapies involving permanent DNA modifications, this approach uses mRNA to temporarily program T cells, reducing long-term risks such as cytokine release syndrome and neurotoxicity. The therapy specifically targets plasma cells expressing BCMA, which produce harmful antibodies, while preserving overall immune function.
If confirmed in phase 3, these results could make this therapy a first-line outpatient treatment, offering lasting relief without the burden of chronic immunosuppression. Researchers are considering extending this mRNA CAR-T platform to lupus, rheumatoid arthritis, and multiple sclerosis.
Major Breakthroughs Against Pancreatic Cancer
Revolution Medicines announces that its KRAS G12C inhibitor, daraxonrasib, allows patients to survive an average of 13.2 months compared to 6.7 months with standard chemotherapy—nearly doubling survival. The company plans to submit these phase III results to the FDA for an approval application.
Actuate Therapeutics publishes results in Nature Medicine showing that elraglusib also doubles one-year survival. This drug attacks pancreatic tumors differently, slowing tumor growth and making the tumor microenvironment more sensitive to chemotherapies and immunotherapies.
The RASolute 302 trial constitutes the first phase 3 trial of a RAS inhibitor in pancreatic cancer, comparing daraxonrasib to standard chemotherapy in metastatic second-line patients. Several potentially revolutionary phase 3 trials begin in 2026 in untreated metastatic pancreatic cancer, testing the addition of targeted therapies to chemotherapy.
The ELI-002 2P vaccine targeting KRAS mutations shows promising results with a median recurrence-free survival not yet reached in patients developing a strong immune response, compared to 3.02 months for other patients.
Lassa Fever Enters the Vaccine Era
The phase 1 trial of the LASSARAB vaccine recruits 55 healthy adults to test three different concentrations, with two injections administered 28 days apart. The vaccine combines a modified inactivated rabies vaccine engineered to express rabies proteins and a surface protein of the Lassa virus called glycoprotein precursor complex.
The Pasteur Institute simultaneously launches the phase Ia MOPEVACLAS trial with 72 healthy volunteers, with first inclusions beginning in early 2026. Lassa fever causes between 100,000 and 300,000 annual cases and 5,000 deaths in West Africa, with a case fatality rate of 1% in general but reaching 18% in hospitalized patients.
The phase 2 IAVI C105/PREVAIL15 trial, funded by CEPI, recruits more than 600 participants in Ghana, Liberia, and Nigeria to test the rVSVΔG-LASV-GPC vaccine candidate. This vaccine represents one of the most advanced in the global pipeline, while Oxford’s ChAdOx1 vaccine enters phase 1 trials with the first volunteer vaccinated in 2025.
Accessibility: The Achilles’ Heel of Personalized Medicine
These personalized treatments remain rarely commercialized and are generally only available within clinical trials, limiting access to eligible patients. The expansion in the number and types of actionable targets in cancer allows precision medicine approaches to reach more patients, but disparities in access persist.
Although mRNA-based CAR-T therapies have been tested clinically for ten years, their clinical translation remains limited due to efficacy compromised by transient mRNA expression. The in vivo approach using lipid nanoparticles significantly reduces costs by avoiding ex vivo cell manipulation and simplifying the therapeutic protocol, improving accessibility for rural or remote patients.
Nigeria bears the largest share of the global burden of Lassa fever, but is not sufficiently at the helm of vaccine research priorities, clinical trials, and preparedness. Strengthening Nigeria’s role as a center for clinical trials through experienced treatment centers and established surveillance systems improves the country’s capacity to conduct clinical trials.
Precision medicine in 2026 reveals transformative potential for targeting pathological mechanisms with unprecedented precision. These clinical trials illustrate innovation and perseverance in medical research, offering promising prospects for treating serious and neglected diseases globally. The challenge now lies in the ability to democratize these innovations so that they benefit the populations that need them most.